Literature DB >> 25301631

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.

Jianjun Zhang1, Junya Fujimoto2, Jianhua Zhang3, David C Wedge4, Xingzhi Song3, Jiexin Zhang5, Sahil Seth3, Chi-Wan Chow2, Yu Cao6, Curtis Gumbs6, Kathryn A Gold7, Neda Kalhor8, Latasha Little6, Harshad Mahadeshwar3, Cesar Moran8, Alexei Protopopov3, Huandong Sun3, Jiabin Tang3, Xifeng Wu9, Yuanqing Ye9, William N William7, J Jack Lee10, John V Heymach11, Waun Ki Hong7, Stephen Swisher12, Ignacio I Wistuba2, P Andrew Futreal13.   

Abstract

Cancers are composed of populations of cells with distinct molecular and phenotypic features, a phenomenon termed intratumor heterogeneity (ITH). ITH in lung cancers has not been well studied. We applied multiregion whole-exome sequencing (WES) on 11 localized lung adenocarcinomas. All tumors showed clear evidence of ITH. On average, 76% of all mutations and 20 out of 21 known cancer gene mutations were identified in all regions of individual tumors, which suggested that single-region sequencing may be adequate to identify the majority of known cancer gene mutations in localized lung adenocarcinomas. With a median follow-up of 21 months after surgery, three patients have relapsed, and all three patients had significantly larger fractions of subclonal mutations in their primary tumors than patients without relapse. These data indicate that a larger subclonal mutation fraction may be associated with increased likelihood of postsurgical relapse in patients with localized lung adenocarcinomas.
Copyright © 2014, American Association for the Advancement of Science.

Entities:  

Mesh:

Year:  2014        PMID: 25301631      PMCID: PMC4354858          DOI: 10.1126/science.1256930

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  41 in total

1.  Performance comparison of benchtop high-throughput sequencing platforms.

Authors:  Nicholas J Loman; Raju V Misra; Timothy J Dallman; Chrystala Constantinidou; Saheer E Gharbia; John Wain; Mark J Pallen
Journal:  Nat Biotechnol       Date:  2012-05       Impact factor: 54.908

2.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.

Authors:  Daniel C Koboldt; Qunyuan Zhang; David E Larson; Dong Shen; Michael D McLellan; Ling Lin; Christopher A Miller; Elaine R Mardis; Li Ding; Richard K Wilson
Journal:  Genome Res       Date:  2012-02-02       Impact factor: 9.043

3.  Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke.

Authors:  P Hainaut; G P Pfeifer
Journal:  Carcinogenesis       Date:  2001-03       Impact factor: 4.944

4.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

Authors:  Andrea Sottoriva; Inmaculada Spiteri; Sara G M Piccirillo; Anestis Touloumis; V Peter Collins; John C Marioni; Christina Curtis; Colin Watts; Simon Tavaré
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-14       Impact factor: 11.205

5.  Tumour evolution inferred by single-cell sequencing.

Authors:  Nicholas Navin; Jude Kendall; Jennifer Troge; Peter Andrews; Linda Rodgers; Jeanne McIndoo; Kerry Cook; Asya Stepansky; Dan Levy; Diane Esposito; Lakshmi Muthuswamy; Alex Krasnitz; W Richard McCombie; James Hicks; Michael Wigler
Journal:  Nature       Date:  2011-03-13       Impact factor: 49.962

6.  Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets.

Authors:  Charles Swanton; James M Larkin; Marco Gerlinger; Aron C Eklund; Michael Howell; Gordon Stamp; Julian Downward; Martin Gore; P Andrew Futreal; Bernard Escudier; Fabrice Andre; Laurence Albiges; Benoit Beuselinck; Stephane Oudard; Jens Hoffmann; Balázs Gyorffy; Chris J Torrance; Karen A Boehme; Hansjuergen Volkmer; Luisella Toschi; Barbara Nicke; Marlene Beck; Zoltan Szallasi
Journal:  Genome Med       Date:  2010-08-11       Impact factor: 11.117

7.  Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:  Marcin Imielinski; Alice H Berger; Peter S Hammerman; Bryan Hernandez; Trevor J Pugh; Eran Hodis; Jeonghee Cho; James Suh; Marzia Capelletti; Andrey Sivachenko; Carrie Sougnez; Daniel Auclair; Michael S Lawrence; Petar Stojanov; Kristian Cibulskis; Kyusam Choi; Luc de Waal; Tanaz Sharifnia; Angela Brooks; Heidi Greulich; Shantanu Banerji; Thomas Zander; Danila Seidel; Frauke Leenders; Sascha Ansén; Corinna Ludwig; Walburga Engel-Riedel; Erich Stoelben; Jürgen Wolf; Chandra Goparju; Kristin Thompson; Wendy Winckler; David Kwiatkowski; Bruce E Johnson; Pasi A Jänne; Vincent A Miller; William Pao; William D Travis; Harvey I Pass; Stacey B Gabriel; Eric S Lander; Roman K Thomas; Levi A Garraway; Gad Getz; Matthew Meyerson
Journal:  Cell       Date:  2012-09-14       Impact factor: 41.582

8.  New aspects in the staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification.

Authors:  H Bülzebruck; R Bopp; P Drings; E Bauer; S Krysa; G Probst; G van Kaick; K M Müller; I Vogt-Moykopf
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

Review 9.  Intratumor heterogeneity: evolution through space and time.

Authors:  Charles Swanton
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

10.  The landscape of cancer genes and mutational processes in breast cancer.

Authors:  Philip J Stephens; Patrick S Tarpey; Helen Davies; Peter Van Loo; Chris Greenman; David C Wedge; Serena Nik-Zainal; Sancha Martin; Ignacio Varela; Graham R Bignell; Lucy R Yates; Elli Papaemmanuil; David Beare; Adam Butler; Angela Cheverton; John Gamble; Jonathan Hinton; Mingming Jia; Alagu Jayakumar; David Jones; Calli Latimer; King Wai Lau; Stuart McLaren; David J McBride; Andrew Menzies; Laura Mudie; Keiran Raine; Roland Rad; Michael Spencer Chapman; Jon Teague; Douglas Easton; Anita Langerød; Ming Ta Michael Lee; Chen-Yang Shen; Benita Tan Kiat Tee; Bernice Wong Huimin; Annegien Broeks; Ana Cristina Vargas; Gulisa Turashvili; John Martens; Aquila Fatima; Penelope Miron; Suet-Feung Chin; Gilles Thomas; Sandrine Boyault; Odette Mariani; Sunil R Lakhani; Marc van de Vijver; Laura van 't Veer; John Foekens; Christine Desmedt; Christos Sotiriou; Andrew Tutt; Carlos Caldas; Jorge S Reis-Filho; Samuel A J R Aparicio; Anne Vincent Salomon; Anne-Lise Børresen-Dale; Andrea L Richardson; Peter J Campbell; P Andrew Futreal; Michael R Stratton
Journal:  Nature       Date:  2012-05-16       Impact factor: 49.962

View more
  398 in total

1.  Prognostic value of computed tomography radiomics features in patients with gastric cancer following curative resection.

Authors:  Wuchao Li; Liwen Zhang; Chong Tian; Hui Song; Mengjie Fang; Chaoen Hu; Yali Zang; Ying Cao; Shiyuan Dai; Fang Wang; Di Dong; Rongpin Wang; Jie Tian
Journal:  Eur Radiol       Date:  2018-12-05       Impact factor: 5.315

2.  Clinical analysis of NSCLC patients reveals lack of association between EGFR mutation and TET1 downregulation.

Authors:  J-I Lai; Y-C Lai; Y-C Chen; N-K Wang; J-N Pan; W-S Wang; S-C Chang
Journal:  Cancer Gene Ther       Date:  2017-08-04       Impact factor: 5.987

Review 3.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

4.  Tumor Heterogeneity--A 'Contemporary Concept' Founded on Historical Insights and Predictions.

Authors:  Danny R Welch
Journal:  Cancer Res       Date:  2016-01-03       Impact factor: 12.701

5.  multiSNV: a probabilistic approach for improving detection of somatic point mutations from multiple related tumour samples.

Authors:  Malvina Josephidou; Andy G Lynch; Simon Tavaré
Journal:  Nucleic Acids Res       Date:  2015-02-26       Impact factor: 16.971

Review 6.  Big Bang Tumor Growth and Clonal Evolution.

Authors:  Ruping Sun; Zheng Hu; Christina Curtis
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

7.  Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.

Authors:  David J VanderWeele; Richard Finney; Kotoe Katayama; Marc Gillard; Gladell Paner; Seiya Imoto; Rui Yamaguchi; David Wheeler; Justin Lack; Maggie Cam; Andrea Pontier; Yen Thi Minh Nguyen; Kazuhiro Maejima; Aya Sasaki-Oku; Kaoru Nakano; Hiroko Tanaka; Donald Vander Griend; Michiaki Kubo; Mark J Ratain; Satoru Miyano; Hidewaki Nakagawa
Journal:  Eur Urol Focus       Date:  2018-02-15

Review 8.  NanoVelcro rare-cell assays for detection and characterization of circulating tumor cells.

Authors:  Yu Jen Jan; Jie-Fu Chen; Yazhen Zhu; Yi-Tsung Lu; Szu Hao Chen; Howard Chung; Matthew Smalley; Yen-Wen Huang; Jiantong Dong; Li-Ching Chen; Hsiao-Hua Yu; James S Tomlinson; Shuang Hou; Vatche G Agopian; Edwin M Posadas; Hsian-Rong Tseng
Journal:  Adv Drug Deliv Rev       Date:  2018-03-15       Impact factor: 15.470

Review 9.  Clonal expansion in non-cancer tissues.

Authors:  Nobuyuki Kakiuchi; Seishi Ogawa
Journal:  Nat Rev Cancer       Date:  2021-02-24       Impact factor: 60.716

Review 10.  Harnessing Tumor Evolution to Circumvent Resistance.

Authors:  Katherine L Pogrebniak; Christina Curtis
Journal:  Trends Genet       Date:  2018-06-11       Impact factor: 11.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.